InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
2
T+90 hit rate
0%
T+90 mean return
-22.4%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Eansor Norman David, Chief Executive Officer. Officer active across 3 companies, notably Marker Therapeutics, Inc.. Aggregated, 9 filings have been logged. Breakdown: 1 buy · 2 sells. Total volume traded: €1.5m. Activity tracked since 8 June 2021. The latest transaction was filed on 16 March 2021 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations9 total
14,285 shares@ US$17.50100.0% of flowCommon StockSEC:0001209191-23-035617:0
Ideal exit: 11 Dec 2021 (T+270)
27,159 shares@ US$125.0541.0% of flowCommon StockSEC:0000914190-21-000405
27,159 shares@ US$125.050.044% mcap41.0% of flowCommon StockSEC:0000914190-21-000405:0
1,538 shares@ US$503.07399.0% of flowCommon StockSEC:0000914190-21-000322
1,538 shares@ US$503.07390.0097% mcap9.0% of flowCommon StockSEC:0000914190-21-000322:0
2,537 shares0Common StockSEC:0000914190-21-000213:0
2,537 shares0Common StockSEC:0000914190-21-000213
12,658 shares0Common StockSEC:0001209191-21-039631:0
12,658 shares0Common StockSEC:0001209191-21-039631
9 of 9 declarations
About Eansor Norman David
Norman David Eansor serves as CEO and President of Protein Sciences at Marker Therapeutics, Inc. and Bio-Techne Corp. In these roles, he is responsible for the strategic and operational direction of the companies. His expertise in the biopharmaceutical sector enables him to drive innovation and enhance the services offered. He plays a key role in achieving growth objectives and developing strategies aimed at strengthening the companies' market position.
